Literature DB >> 20959308

The decrease of β-synuclein in cortical brain areas defines a molecular subgroup of dementia with Lewy bodies.

Katrin Beyer1, Montserrat Domingo-Sàbat, Cristina Santos, Eduardo Tolosa, Isidro Ferrer, Aurelio Ariza.   

Abstract

Lewy body diseases include dementia with Lewy bodies and Parkinson's disease. Whereas dementia with Lewy bodies and Parkinson's disease can be distinguished as separate clinical entities, the pathological picture is very often identical. α-synuclein aggregation is a key event in the pathogenesis of Lewy body diseases and β-synuclein inhibits α-synuclein aggregation in vitro and in vivo. Recently, β-synuclein has been shown to interact directly with α-synuclein, regulating its functionality and preventing its oligomerization. In this study, we analysed the expression of two β-synuclein transcript variants and the main α-synuclein transcript SNCA140, in frozen samples of three areas from brains of patients with (i) pure diffuse Lewy body pathology; (ii) pure Alzheimer's disease pathology; (iii) diffuse Lewy body pathology and concomitant Alzheimer's disease pathology and (iv) controls. Relative messenger RNA expression was determined by real-time polymerase chain reaction, expression changes were evaluated by the ΔΔC(t) method and messenger RNA expression data were confirmed at the protein level. A drastic diminution of β-synuclein expression was observed in cortical areas of all samples that presented neuropathological features corresponding to pure diffuse Lewy body pathology and the clinical phenotype of dementia with Lewy bodies, but not in those with neuropathological features corresponding to diffuse Lewy body pathology and concomitant Alzheimer's disease pathology or the clinical phenotype of Parkinson's disease with dementia. The correlation of expression data with the clinical phenotype and neuropathological diagnosis of the patients suggested the existence of a specific molecular subtype of dementia with Lewy bodies, characterized by a strong decrease of β-synuclein in the frontal and temporal cortices. Furthermore, our findings provide new insights into the pathogenesis of Lewy body diseases that may be important for the understanding of molecular mechanisms involved in these complex diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959308     DOI: 10.1093/brain/awq275

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  14 in total

1.  New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases.

Authors:  Katrin Beyer; Ana M Munoz-Marmol; Carolina Sanz; Ruth Marginet-Flinch; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2011-12-29       Impact factor: 2.660

Review 2.  Fluid markers of synapse degeneration in synucleinopathies.

Authors:  Alba Cervantes González; Olivia Belbin
Journal:  J Neural Transm (Vienna)       Date:  2022-02-11       Impact factor: 3.575

Review 3.  α-Synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration.

Authors:  Katrin Beyer; Aurelio Ariza
Journal:  Mol Neurobiol       Date:  2012-08-25       Impact factor: 5.590

Review 4.  The Role of α-Synuclein and LRRK2 in Tau Phosphorylation.

Authors:  Fumitaka Kawakami; Takafumi Ichikawa
Journal:  Parkinsons Dis       Date:  2015-04-21

5.  iTRAQ-based Proteomic Analysis of APPSw,Ind Mice Provides Insights into the Early Changes in Alzheimer's Disease.

Authors:  Nan Li; Pinghong Hu; Tiantian Xu; Huan Chen; Xiaoying Chen; Jianwen Hu; Xifei Yang; Lei Shi; Jian-Hong Luo; Junyu Xu
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

6.  Unveiling a Selective Mechanism for the Inhibition of α-Synuclein Aggregation by β-Synuclein.

Authors:  Andre Leitao; Akshay Bhumkar; Dominic J B Hunter; Yann Gambin; Emma Sierecki
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

Review 7.  Possible alterations in β-Synuclein, the non-amyloidogenic homologue of α-Synuclein, during progression of sporadic α-synucleinopathies.

Authors:  Masayo Fujita; Akio Sekigawa; Kazunari Sekiyama; Yoshiki Takamatsu; Makoto Hashimoto
Journal:  Int J Mol Sci       Date:  2012-09-14       Impact factor: 6.208

8.  Molecular ageing of alpha- and Beta-synucleins: protein damage and repair mechanisms.

Authors:  Vasanthy Vigneswara; Simon Cass; Declan Wayne; Edward L Bolt; David E Ray; Wayne G Carter
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

Review 9.  Implications of DNA Methylation in Parkinson's Disease.

Authors:  Ernesto Miranda-Morales; Karin Meier; Ada Sandoval-Carrillo; José Salas-Pacheco; Paola Vázquez-Cárdenas; Oscar Arias-Carrión
Journal:  Front Mol Neurosci       Date:  2017-07-18       Impact factor: 5.639

Review 10.  Alternative Splicing of Alpha- and Beta-Synuclein Genes Plays Differential Roles in Synucleinopathies.

Authors:  Ana Gámez-Valero; Katrin Beyer
Journal:  Genes (Basel)       Date:  2018-01-25       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.